mCERAD_{SOT}

Amyloid phase

% Amyloid IHC

Dx AD (NIARI)

Dx AD (NIAAA)

Braak stage

Cortical atrophy

SUVR

Dementia

BIE positivity
  

(Quantitative)

(Ordinal)

(Quantitative)

(Ordinal)

(Ordinal)

(Ordinal)

(Ordinal)

(Quantitative)

(Nominal)

(Nominal)
  

P < 0.0001

P < 0.0001

P = 0.0005

P < 0.0001

P < 0.0001

P < 0.0001

P = 0.2518

P < 0.0001

P = 0.0009

P < 0.0001

CERAD

(Ordinal)


P < 0.0001

P = 0.0014

P < 0.0001

P < 0.0001

P < 0.0001

P = 0.3569

P < 0.0001

P = 0.0021

P < 0.0001

mCERAD_{SOT}

(Quantitative)

 
P < 0.0001

P < 0.0001

P < 0.0001

P < 0.0001

P = 0.6275

P < 0.0001

P < 0.0001

P < 0.0001

Amyloid Phase

(Ordinal)

  
P = 0.0001

P < 0.0001

P = 0.0001

P = 0.9266

P < 0.0001

P = 0.8746

P < 0.0001

% amyloid IHC

(Quantitative)

   
P < 0.0001

P < 0.0001

P = 0.2087

P < 0.0001

P < 0.0001

P < 0.0001

AD (NIARI)

(Ordinal)

    
P < 0.0001

P = 0.2758

P < 0.0001

P < 0.0001

P < 0.0001

AD (NIAAA)

(Ordinal)

     
P = 0.4195

P < 0.0001

P < 0.0001

P < 0.0001

Braak Stage

(Ordinal)

      
P = 0.1778

P = 0.4006

P = 0.7397

Cortical atrophy

(Ordinal)

       
P = 0.0041

P < 0.0001

SUVR

(Quantitative)

        
P < 0.0001

Dementia

(Nominal)


mCERAD
_{
SOT
} modified CERAD Standard of Truth, IHC Immunohistochemistry, Dx AD (NIARI) Neuropathological diagnosis of AD likelihood using the National Institute of Ageing – Reagan Institute criteria [9], Dx AD (NIAAA) Neuropathological diagnosis of AD likelihood using the National Institute of Ageing – Alzheimer’s Association criteria [8], SUVR Standard retention value ratio normalised to the cerebellar cortex, BIE Blinded Image evaluation of PET images, CERAD Consortium to Establish a Registry for Alzheimer’s Disease
 Statistical tests were performed as indicated in the insert panel. mCERADSOT, % area amyloid IHC and SUVR values are continuous variables. All other variables are either categorical; CERAD (None, Sparse, Moderate, Frequent); Amyloid Phase (phases 0, 1, 2, 3, 4 and 5); Dx AD (NIARI) (Normal, Low, Intermediate or High  likelihood of AD), Dx AD (NIARI) (Not, Low, Intermediate or High – level of AD neuropathologic change), Braak Stage (Stage 0, I, II, III, IV, V and VI); Cortical atrophy (None, Mild, Moderate, Severe), or nominal; Dementia (Yes or No); BIE positivity (Normal Abnormal). All tests were performed using Spearman except BIE positivity vs Dementia which was perfomed using Chisquare test. Plots for some BIE positivity correlations are presented in Figs. 2 and 4